Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 2:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Naloxone-Only Clear all
Completed Phase 1 Interventional

Drug-Drug Interaction Study Between Telaprevir and Buprenorphine

NCT01275599
View directory record Official record
Conditions
Hepatitis C, Opioid-Related Disorders
Interventions
telaprevir, buprenorphine/naloxone
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 64 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Overland Park, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 28, 2026, 2:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of Naloxone 5 Milligrams (mg) Intramuscular (IM) Autoinjector

NCT05264493
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NaxRedy ™, Naloxone Hydrochloride Injection, USP
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 28, 2026, 2:10 AM EDT
Recruiting Early Phase 1 Interventional

A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use

NCT06726200
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine + naloxone (Suboxone), Buprenorphine Injection
Drug
Lead sponsor
Rachel R. Luba
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 28, 2026, 2:10 AM EDT
Completed Phase 4 Interventional Results available

ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults

NCT00511836
View directory record Official record
Conditions
Alcohol Dependence
Interventions
VIVITROL 380 mg, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 28, 2026, 2:10 AM EDT
Recruiting Early Phase 1 Interventional

Naltrexone Neuroimaging in Teens With Eating Disorders

NCT05509257
View directory record Official record
Conditions
Eating Disorders, Binge Eating, Purging (Eating Disorders), Bulimia Nervosa, Anorexia Nervosa, Atypical
Interventions
Naltrexone, Placebo
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
13 Years to 21 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 28, 2026, 2:10 AM EDT
Terminated Not applicable Interventional

Recovery After Dialysis-Requiring Acute Kidney Injury

NCT03305549
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Conservative dialysis strategy, TIW dialysis strategy
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 28, 2026, 2:10 AM EDT
Not yet recruiting Phase 2 Interventional

Naloxone for Opioid Associated Out of Hospital Cardiac Arrest

NCT06251609
View directory record Official record
Conditions
Heart Arrest, Out-Of-Hospital, Opioid Overdose, Naloxone
Interventions
Naloxone 2 MG, Saline 2ml
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 28, 2026, 2:10 AM EDT
Active, not recruiting Not applicable Interventional

Community-based Education, Navigation, and Support Intervention for Military Veterans

NCT05343169
View directory record Official record
Conditions
Overdose, Opioid Use Disorder, HIV Infections
Interventions
Overdose Education and Naloxone Distribution, Advanced Education in Safer Substance Use, Treatment, and Self-Care, Social Service and Health Navigation, Peer Social Support
Behavioral
Lead sponsor
New York University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 28, 2026, 2:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Buprenorphine for Prisoners

NCT00574067
View directory record Official record
Conditions
Heroin Addiction
Interventions
Buprenorphine +OTP, Buprenorphine +CHC, Counseling +OTP, Counseling +CHC
Drug
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years to 60 Years
Enrollment
213 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Jessup, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 28, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Will Having Alcohol Treatment Improve Functioning?

NCT01245647
View directory record Official record
Conditions
HIV, Alcoholism
Interventions
Naltrexone, 50mg, once per day for 4 months, Sugar pill, 50mg, once per day for 4 months
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Jacksonville, Florida • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2018 · Synced Sep 28, 2026, 2:10 AM EDT
Completed Phase 4 Interventional Results available

Treatment for Alcoholism and Post-Traumatic Stress Disorder (Naltrexone)

NCT00006489
View directory record Official record
Conditions
Alcoholism, Alcohol Dependence, Post-Traumatic Stress Disorder
Interventions
Cognitive-Behavioral Therapy, Naltrexone, Placebo
Behavioral · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Sep 28, 2026, 2:10 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers Results available

Buprenorphine Physician-Pharmacist Collaboration in the Management of Patients With Opioid Use Disorder: CTN 0075

NCT03248947
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
buprenorphine/naloxone, Pharmacist-administered buprenorphine/naloxone maintenance care
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
6
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Sep 28, 2026, 2:10 AM EDT
Active, not recruiting Phase 3 Interventional

Behavioral Pharmacological Examination of a Novel Buprenorphine Induction Method Among Individuals Who Use Fentanyl

NCT06089707
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Naloxone Nasal Spray
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 28, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate

NCT01950520
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Propranolol, Pindolol, Dantrolene, Magnesium Sulfate, Caffeine, Qsymia, Topiramate, Phentermine, Naltrexone, Mirabegron 50mg, Mirabegron 200mg, Placebo Cohort 1, Placebo Cohort 2, Placebo for Mirabegron
Drug · Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 35 Years · Male only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 28, 2026, 2:10 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade

NCT07459166
View directory record Official record
Conditions
Fentanyl Overdose, Fentanyl Poisoning
Interventions
Naloxone Hydrochloride, Fentanyl, Sterile Saline, CS-1103
Drug
Lead sponsor
Clear Scientific, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 28, 2026, 2:10 AM EDT
Completed Not applicable Interventional

Randomized, Double-Blind Cross-Over Trial Of Buprenorphine and Low-Dose Naloxone Versus Buprenorphine

NCT00679458
View directory record Official record
Conditions
Pain
Interventions
buprenorphine and low-dose naloxone, buprenorphine alone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2010 · Synced Sep 28, 2026, 2:10 AM EDT
Completed Phase 1 Interventional

Single Ascending Dose Study of RBP-6000

NCT03002961
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
RBP-6000, Suboxone
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 25, 2016 · Synced Sep 28, 2026, 2:10 AM EDT
Completed Phase 2 Interventional Results available

Effect of Topical Naltrexone Ophthalmic Solution on the Signs and Symptoms of Dry Eye in Diabetic Subjects

NCT03660475
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Naltrexone, Placebos
Drug
Lead sponsor
Sassani, Joseph S., MD, MHA
Individual
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Sep 28, 2026, 2:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Ethanol on Oxycodone Pharmacokinetics in Healthy Volunteers

NCT02165930
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone, Naltrexone
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
21 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Sep 28, 2026, 2:10 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone

NCT00880841
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine / Naloxone
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 28, 2026, 2:10 AM EDT
Completed Phase 2 Interventional

Cariprazine for Comorbid Cocaine and Opioid Use Disorder

NCT05063201
View directory record Official record
Conditions
Opioid-use Disorder, Cocaine Use Disorder
Interventions
Cariprazine 1.5 MG, Placebo
Drug
Lead sponsor
Kyle Kampman
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 28, 2026, 2:10 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Effects of Naltrexone on Nocturnal Breathing Patterns at Altitude

NCT05037032
View directory record Official record
Conditions
Altitude, Sleep Apnea, Central
Interventions
Naltrexone Pill, Placebo
Drug
Lead sponsor
VA Loma Linda Health Care System
Federal
Eligibility
18 Years to 35 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 28, 2026, 2:10 AM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of NTC-510 to Treat Pain Following Dental Surgery of Third Molars

NCT02161354
View directory record Official record
Conditions
Dental Pain
Interventions
NTC-510 capsules, Placebo Capsules, NTC-510A Capsules
Drug
Lead sponsor
NanoSHIFT LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Sep 28, 2026, 2:10 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Adherence Tool to Manage Narcotic -Addicted HIV Patients

NCT02194764
View directory record Official record
Conditions
Healthy Adults
Interventions
Naltrexone and 2-butanol, 2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form)
Drug
Lead sponsor
Xhale Assurance
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Sep 28, 2026, 2:10 AM EDT